{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:47:24Z","timestamp":1782092844480,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":65,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Guangxi Research Basic Ability Improvement Project for Young and Middle-aged Teachers","award":["2024KY0128"],"award-info":[{"award-number":["2024KY0128"]}]},{"name":"the National Funded Postdoctoral Researcher Program","award":["GZC20230583"],"award-info":[{"award-number":["GZC20230583"]}]},{"name":"oung Investigator Program","award":["2025GXNSFBA069037"],"award-info":[{"award-number":["2025GXNSFBA069037"]}]},{"name":"Guangxi Natural Science Foundation","award":["2024GXNSFDA010029"],"award-info":[{"award-number":["2024GXNSFDA010029"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82560579"],"award-info":[{"award-number":["82560579"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Special Fund for Clinical Discipline Construction of Guangxi Medical University","award":["GXMULJZ202402"],"award-info":[{"award-number":["GXMULJZ202402"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Surg"],"DOI":"10.1186\/s12893-026-03752-z","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T01:37:49Z","timestamp":1776476269000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant or conversion therapy nullifies the prognostic impact of surgical margin width in hepatocellular carcinoma: a single-center retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Haixiang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huasheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongguang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjiu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengkun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangzhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangye","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"key":"3752_CR1","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021.","DOI":"10.3322\/caac.21660"},{"issue":"5","key":"3752_CR2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1097\/SLA.0000000000002889","volume":"268","author":"AD Pinna","year":"2018","unstructured":"Pinna AD, Yang T, Mazzaferro V, De Carlis L, Zhou J, Roayaie S, et al. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg. 2018;268(5):868\u201375.","journal-title":"Ann Surg"},{"issue":"5","key":"3752_CR3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1097\/SLA.0000000000000710","volume":"261","author":"P Tabrizian","year":"2015","unstructured":"Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261(5):947\u201355.","journal-title":"Ann Surg"},{"issue":"37","key":"3752_CR4","doi-asserted-by":"publisher","first-page":"e8043","DOI":"10.1097\/MD.0000000000008043","volume":"96","author":"FP Zhong","year":"2017","unstructured":"Zhong FP, Zhang YJ, Liu Y, Zou SB. Prognostic impact of surgical margin in patients with hepatocellular carcinoma: a meta-analysis. Med (Baltim). 2017;96(37):e8043.","journal-title":"Med (Baltim)"},{"key":"3752_CR5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3389\/fmed.2020.00139","volume":"7","author":"H Wang","year":"2020","unstructured":"Wang H, Yu H, Qian YW, Cao ZY, Wu MC, Cong WM. Impact of surgical margin on the prognosis of early hepatocellular carcinoma (\u2264\u20095 cm): a propensity score matching analysis. Front Med (Lausanne). 2020;7:139.","journal-title":"Front Med (Lausanne)"},{"key":"3752_CR6","doi-asserted-by":"publisher","first-page":"610636","DOI":"10.3389\/fonc.2020.610636","volume":"10","author":"L Liu","year":"2020","unstructured":"Liu L, Shui Y, Yu Q, Guo Y, Zhang L, Zhou X, et al. Narrow-margin hepatectomy resulted in higher recurrence and lower overall survival for R0 resection hepatocellular carcinoma. Front Oncol. 2020;10:610636.","journal-title":"Front Oncol"},{"key":"3752_CR7","doi-asserted-by":"crossref","unstructured":"Singal AG, Yarchoan M, Yopp A, Sapisochin G, Pinato DJ, Pillai A. Neoadjuvant and adjuvant systemic therapy in HCC: current status and the future. Hepatol Commun. 2024;8(6).","DOI":"10.1097\/HC9.0000000000000430"},{"issue":"7","key":"3752_CR8","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1111\/cas.16194","volume":"115","author":"MD Wang","year":"2024","unstructured":"Wang MD, Xu XJ, Wang KC, Diao YK, Xu JH, Gu LH, et al. Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: current status, challenges and opportunities. Cancer Sci. 2024;115(7):2159\u201369.","journal-title":"Cancer Sci"},{"issue":"2","key":"3752_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.21037\/hbsn-21-328","volume":"11","author":"HC Sun","year":"2022","unstructured":"Sun HC, Zhou J, Wang Z, Liu X, Xie Q, Jia W, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surg Nutr. 2022;11(2):227\u201352.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"3752_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.21037\/hbsn-20-480","volume":"9","author":"DY Xie","year":"2020","unstructured":"Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9(4):452\u201363.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"3","key":"3752_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.21037\/hbsn-23-204","volume":"12","author":"R Matsuki","year":"2023","unstructured":"Matsuki R, Kogure M, Hasui N, Momose H, Suzuki Y, Sakamoto Y. Development of conversion therapy for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2023;12(3):453\u20136.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3752_CR12","doi-asserted-by":"crossref","unstructured":"Zeng Z, Huang H, Zhu G, Zeng J, Ye X, Su H, et al. Sequential hepatectomy for hepatocellular carcinoma with inadequate future-liver-remnant after portal vein ligation in combination with apatinib plus camrelizumab (PLACES): a single-arm prospective pilot study. Hepatobiliary Surgery and Nutrition; 2025.","DOI":"10.21037\/hbsn-24-363"},{"issue":"9","key":"3752_CR13","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1080\/00365521.2022.2057198","volume":"57","author":"S Mi","year":"2022","unstructured":"Mi S, Nie Y, Xie C. Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Scand J Gastroenterol. 2022;57(9):1070\u20139.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"3752_CR14","doi-asserted-by":"publisher","first-page":"7734","DOI":"10.1002\/cam4.5529","volume":"12","author":"A Mo","year":"2023","unstructured":"Mo A, Zhang Q, Xia F, Huang Z, Peng S, Cao W, et al. Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (\u2265\u20095 cm): multicenter retrospective study. Cancer Med. 2023;12(7):7734\u201347.","journal-title":"Cancer Med"},{"issue":"15suppl","key":"3752_CR15","doi-asserted-by":"publisher","first-page":"4008","DOI":"10.1200\/JCO.2021.39.15_suppl.4008","volume":"39","author":"S Li","year":"2021","unstructured":"Li S, Zhong C, Li Q, Zou J, Wang Q, Shang C, et al. Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A\/B hepatocellular carcinoma patients beyond Milan criteria: an interim analysis of a multi-center, phase 3, randomized, controlled clinical trial. J Clin Oncol. 2021;39(15suppl):4008.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3752_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"1","key":"3752_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2022.09.006","volume":"78","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, et al. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: a subanalysis of the REFLECT study. J Hepatol. 2023;78(1):133\u201341.","journal-title":"J Hepatol"},{"issue":"5","key":"3752_CR18","doi-asserted-by":"publisher","first-page":"109588","DOI":"10.1016\/j.ejso.2025.109588","volume":"51","author":"W Bo","year":"2025","unstructured":"Bo W, Zhang L, Chen Y, Zhang J, Wang H. Neoadjuvant therapy with triple therapy for centrally located hepatocellular carcinoma. Eur J Surg Oncol. 2025;51(5):109588.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"3752_CR19","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/s43018-021-00234-4","volume":"2","author":"WJ Ho","year":"2021","unstructured":"Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, et al. Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2021;2(9):891\u2013903.","journal-title":"Nat Cancer"},{"issue":"2","key":"3752_CR20","first-page":"277","volume":"31","author":"Expert committee of","year":"2024","unstructured":"Expert committee of. the d, treatment of primary liver c. Guideline for the diagnosis and treatment of primary liver cancer (2024 edition). Chin J Clin Med. 2024;31(2):277\u2013334.","journal-title":"Chin J Clin Med"},{"issue":"6","key":"3752_CR21","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1007\/BF01659097","volume":"17","author":"EC Lai","year":"1993","unstructured":"Lai EC, You KT, Ng IO, Shek TW. The pathological basis of resection margin for hepatocellular carcinoma. World J Surg. 1993;17(6):786\u201390. discussion 91.","journal-title":"World J Surg"},{"issue":"3","key":"3752_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nrclinonc.2016.195","volume":"14","author":"S Liti\u00e8re","year":"2017","unstructured":"Liti\u00e8re S, Collette S, de Vries EGE, Seymour L, Bogaerts J. RECIST - learning from the past to build the future. Nat Rev Clin Oncol. 2017;14(3):187\u201392.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"3752_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"5","key":"3752_CR24","first-page":"2052","volume":"27","author":"WD Lin","year":"2023","unstructured":"Lin WD, Ye LN, Song ZS, Wang KP, Feng YF, Pan CY. Wide surgical margins improve prognosis for HCC with microvascular invasion. Eur Rev Med Pharmacol Sci. 2023;27(5):2052\u20139.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3752_CR25","doi-asserted-by":"publisher","first-page":"103107","DOI":"10.1016\/j.ebiom.2020.103107","volume":"62","author":"KQ Zhou","year":"2020","unstructured":"Zhou KQ, Sun YF, Cheng JW, Du M, Ji Y, Wang PX, et al. Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. EBioMedicine. 2020;62:103107.","journal-title":"EBioMedicine"},{"issue":"8","key":"3752_CR26","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.hpb.2018.11.005","volume":"21","author":"J Han","year":"2019","unstructured":"Han J, Li ZL, Xing H, Wu H, Zhu P, Lau WY, et al. The impact of resection margin and microvascular invasion on long-term prognosis after curative resection of hepatocellular carcinoma: a multi-institutional study. HPB (Oxford). 2019;21(8):962\u201371.","journal-title":"HPB (Oxford)"},{"issue":"4","key":"3752_CR27","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.surg.2018.09.016","volume":"165","author":"P Yang","year":"2019","unstructured":"Yang P, Si A, Yang J, Cheng Z, Wang K, Li J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion. Surgery. 2019;165(4):721\u201330.","journal-title":"Surgery"},{"key":"3752_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.suronc.2020.11.009","volume":"36","author":"CM Su","year":"2021","unstructured":"Su CM, Chou CC, Yang TH, Lin YJ. Comparison of anatomic and non-anatomic resections for very early-stage hepatocellular carcinoma: the importance of surgical resection margin width in non-anatomic resection. Surg Oncol. 2021;36:15\u201322.","journal-title":"Surg Oncol"},{"issue":"1","key":"3752_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12957-022-02770-4","volume":"20","author":"XM Dai","year":"2022","unstructured":"Dai XM, Xiang ZQ, Wang Q, Li HJ, Zhu Z. Oncological outcomes of anatomic versus non-anatomic resections for small hepatocellular carcinoma: systematic review and meta-analysis of propensity-score matched studies. World J Surg Oncol. 2022;20(1):299.","journal-title":"World J Surg Oncol"},{"issue":"6","key":"3752_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamasurg.2013.4648","volume":"149","author":"G Huang","year":"2014","unstructured":"Huang G, Lau WY, Zhou WP, Shen F, Pan ZY, Yuan SX, et al. Prediction of hepatocellular carcinoma recurrence in patients with low hepatitis B virus DNA levels and high preoperative hepatitis B surface antigen levels. JAMA Surg. 2014;149(6):519\u201327.","journal-title":"JAMA Surg"},{"issue":"3","key":"3752_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/SLA.0b013e318262b218","volume":"257","author":"G Huang","year":"2013","unstructured":"Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257(3):490\u2013505.","journal-title":"Ann Surg"},{"issue":"5","key":"3752_CR32","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1245\/s10434-012-2803-7","volume":"20","author":"G Huang","year":"2013","unstructured":"Huang G, Yang Y, Shen F, Pan ZY, Fu SY, Lau WY, et al. Early viral suppression predicts good postoperative survivals in patients with hepatocellular carcinoma with a high baseline HBV-DNA load. Ann Surg Oncol. 2013;20(5):1482\u201390.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"3752_CR33","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1200\/JCO.22.01142","volume":"41","author":"SH Li","year":"2023","unstructured":"Li SH, Mei J, Cheng Y, Li Q, Wang QX, Fang CK, et al. Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, phase iii, randomized study. J Clin oncology: official J Am Soc Clin Oncol. 2023;41(10):1898\u2013908.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"12","key":"3752_CR34","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","volume":"6","author":"J Liu","year":"2016","unstructured":"Liu J, Blake SJ, Yong MC, Harjunp\u00e4\u00e4 H, Ngiow SF, Takeda K, et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 2016;6(12):1382\u201399.","journal-title":"Cancer Discov"},{"issue":"10","key":"3752_CR35","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ejso.2018.05.018","volume":"44","author":"S Famularo","year":"2018","unstructured":"Famularo S, Di Sandro S, Giani A, Lauterio A, Sandini M, De Carlis R, et al. Long-term oncologic results of anatomic vs. parenchyma-sparing resection for hepatocellular carcinoma. A propensity score-matching analysis. Eur J Surg Oncol. 2018;44(10):1580\u20137.","journal-title":"Eur J Surg Oncol"},{"issue":"8","key":"3752_CR36","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1007\/s00464-014-3924-9","volume":"29","author":"C Conrad","year":"2015","unstructured":"Conrad C, Ogiso S, Inoue Y, Shivathirthan N, Gayet B. Laparoscopic parenchymal-sparing liver resection of lesions in the central segments: feasible, safe, and effective. Surg Endosc. 2015;29(8):2410\u20137.","journal-title":"Surg Endosc"},{"issue":"5","key":"3752_CR37","first-page":"1176","volume":"26","author":"K Kubota","year":"1997","unstructured":"Kubota K, Makuuchi M, Kusaka K, Kobayashi T, Miki K, Hasegawa K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26(5):1176\u201381.","journal-title":"Hepatology"},{"issue":"1","key":"3752_CR38","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.surg.2016.02.009","volume":"160","author":"T Sumiyoshi","year":"2016","unstructured":"Sumiyoshi T, Shima Y, Okabayashi T, Kozuki A, Hata Y, Noda Y, et al. Liver function assessment using 99mTc-GSA single-photon emission computed tomography (SPECT)\/CT fusion imaging in hilar bile duct cancer: a retrospective study. Surgery. 2016;160(1):118\u201326.","journal-title":"Surgery"},{"key":"3752_CR39","doi-asserted-by":"publisher","first-page":"117955491882545","DOI":"10.1177\/1179554918825450","volume":"13","author":"M Desjardin","year":"2019","unstructured":"Desjardin M, Bonhomme B, Le Bail B, Evrard S, Brouste V, Desolneux G, et al. Hepatotoxicities induced by neoadjuvant chemotherapy in colorectal cancer liver metastases: distinguishing the true from the false. Clin Med Insights Oncol. 2019;13:1179554918825450.","journal-title":"Clin Med Insights Oncol"},{"issue":"5","key":"3752_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41419-020-2558-1","volume":"11","author":"MA Rodr\u00edguez-Hern\u00e1ndez","year":"2020","unstructured":"Rodr\u00edguez-Hern\u00e1ndez MA, Chapresto-Garz\u00f3n R, Cadenas M, Navarro-Villar\u00e1n E, Negrete M, G\u00f3mez-Bravo MA, et al. Differential effectiveness of tyrosine kinase inhibitors in 2D\/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells. Cell Death Dis. 2020;11(5):339.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3752_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/jso.22060","volume":"105","author":"TH Wu","year":"2012","unstructured":"Wu TH, Yu MC, Chen TC, Lee CF, Chan KM, Wu TJ, et al. Encapsulation is a significant prognostic factor for better outcome in large hepatocellular carcinoma. J Surg Oncol. 2012;105(1):85\u201390.","journal-title":"J Surg Oncol"},{"issue":"1","key":"3752_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00268-021-06308-9","volume":"46","author":"SK Hong","year":"2022","unstructured":"Hong SK, Jin XL, Suh S, Hong SY, Hong K, Han ES, et al. Different risk factors for early and late recurrence after curative resection of hepatocellular carcinoma. World J Surg. 2022;46(1):197\u2013206.","journal-title":"World J Surg"},{"issue":"1","key":"3752_CR43","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40880-019-0404-6","volume":"39","author":"YX Pan","year":"2019","unstructured":"Pan YX, Chen JC, Fang AP, Wang XH, Chen JB, Wang JC, et al. A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomy. Cancer Commun (London England). 2019;39(1):55.","journal-title":"Cancer Commun (London England)"},{"issue":"16suppl","key":"3752_CR44","doi-asserted-by":"publisher","first-page":"e16160","DOI":"10.1200\/JCO.2023.41.16_suppl.e16160","volume":"41","author":"W Dong","year":"2023","unstructured":"Dong W, Zhang S, Huo Z, Lu J, Liu H, Wang P, et al. Lenvatinib in combination with PD-1 inhibitor and hepatic arterial infusion chemotherapy (HAIC) for patients with potentially resectable hepatocellular carcinoma: a retrospective analysis. J Clin Oncol. 2023;41(16suppl):e16160\u2013e.","journal-title":"J Clin Oncol"},{"issue":"16suppl","key":"3752_CR45","doi-asserted-by":"publisher","first-page":"4072","DOI":"10.1200\/JCO.2023.41.16_suppl.4072","volume":"41","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Yan M, Chen Y, Wu X, Yang L, Yin Z, et al. Transarterial chemoembolization combined with lenvatinib and camrelizumab for unresectable hepatocellular carcinoma: a prospective, single-arm, multicenter study. J Clin Oncol. 2023;41(16suppl):4072.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3752_CR46","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(08)70003-2","volume":"9","author":"S Wu","year":"2008","unstructured":"Wu S, Chen JJ, Kudelka A, Lu J, Zhu X. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117\u201323.","journal-title":"Lancet Oncol"},{"issue":"12","key":"3752_CR47","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.2217\/fon.14.42","volume":"10","author":"O Abdel-Rahman","year":"2014","unstructured":"Abdel-Rahman O, Fouad M. Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis. Future Oncol. 2014;10(12):1981\u201392.","journal-title":"Future Oncol"},{"issue":"10408","key":"3752_CR48","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet (London England). 2023;402(10408):1133\u201346.","journal-title":"Lancet (London England)"}],"container-title":["BMC Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12893-026-03752-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-026-03752-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12893-026-03752-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T01:02:07Z","timestamp":1782090127000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12893-026-03752-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3752"],"URL":"https:\/\/doi.org\/10.1186\/s12893-026-03752-z","relation":{},"ISSN":["1471-2482"],"issn-type":[{"value":"1471-2482","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"1 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study had acquired the approval of the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University before clinical data collection. Approval Number: NO. 2024-E624-01. Informed consent was obtained from all individual participants included in the study. We declare that this study was conducted on human beings and\/or human data in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}